Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
  • C07D285/01—Five-membered rings
  • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
  • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
  • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

• the invention relates to new substituted thiadiazole sulfonamides, processes for their preparation and use thereof as medicaments.
• interleukin-ß IL-1 ß
• IL-1 ß interleukin-ß
• R 3 - (R 4 ) N- in which R 3 and R 4 are identical or different and denote hydrogen atom or (CC 6 ) -alkyl-, or 3. a heteroaromatic from the following group 3.1. to 3.15. who are unsubstituted or as under 2.1 to 2.12. is substituted,
• R 2 is 1. (CrC 7 ) alkyl, in which alkyl is branched or unbranched and is unsubstituted or mono- or disubstituted as above under 2.1 to 2.12. described or is substituted by a heteroalkyl ring or by a (C 3 -C 7 ) cycloalkyl, in which the heteroalkyl ring or the (C 3 -C 7 ) cycloalkyl is unsubstituted or mono- or disubstituted as above under 2.1 to 2.12. is substituted,
• Phenyl in which phenyl is unsubstituted or mono- or disubstituted as above under 2.1. up to 2J2. is substituted,
• R 7 represents the residue of an ⁇ -amino acid, or R 8 and R 7 together with the carbon atom to which they are attached is a 4- to 7-membered
• R 2 and R 3 together with the nitrogen to which they are attached are a 4- to 7-membered member Form a ring, optionally one of the
• Carbon atoms is replaced by -O-, -S- or -NH-, and wherein one, two or three of the carbon atoms in the ring are unsubstituted or mono- or disubstituted by
• R 3 represents hydrogen atom or (CC 6 ) alkyl, and / or
• R 3 and R 4 are identical or different and denote hydrogen atom or (CrC 6 ) alkyl-
• R 3 stands for hydrogen atom or methyl
• R 2 stands for 1.
• (CrC 4 ) -alkyl in which alkyl is branched or unbranched and is unsubstituted or simply as under 2.1 to 2.12. described or substituted by phenyl or by a heteroalkyl ring or by a (C 3 -C) - cycloalkyl, in which the heteroalkyl ring or the (C 3 -C 7 ) - cycloalkyl is unsubstituted or mono- or disubstituted as in 2.1 to 2.12 . is substituted,
• R 2 and R 3 together with the nitrogen to which they are attached form a 4- to 7-membered ring, in which one of the carbon atoms is optionally replaced by -O-, -S- or -NH-, and in which one, two or three of the carbon atoms in the ring are unsubstituted or mono- or disubstituted by
• R 3 is hydrogen atom or Represents (CC 6 ) alkyl, or wherein the hydrogen atom in the optionally present -NH- is unsubstituted in the ring or by a) (CC 3 ) alkyl, b) -C (O) -R 3 , wherein R 3 is hydrogen atom or Represents (CC 6 ) alkyl, c) phenyl- (CH 2 ) 0 -, in which phenyl is unsubstituted or mono- or disubstituted as under 2.1 to 2.12.
• o represents the integer zero, 1 or 2, or d) C (O) -O- (CC 3 ) alkyl is substituted, and / or 4.8 two carbon atoms in the ring form part of an additional phenyl radical.
• a compound of the formula I is particularly preferred, where R 1 is 1. phenyl or 2. phenyl which is simply substituted by
• R 3 represents hydrogen atom or methyl
• R 2 represents 1. (CrC 4 ) alkyl, in which alkyl is branched or unbranched and is unsubstituted or simply substituted by phenyl, C (O) -OH, halogen, piperidine or cyclohexyl, in which Piperidine or cyclohexyl is unsubstituted or mono- or disubstituted by halogen or C (O) -OH, 2. cyclohexyl, 3.
• R 8 represents a hydrogen atom
• R 7 is methyl
• X is -OH or -OR 6
• R 6 is benzyl or (CC 3 ) -alkyl, or 4.
• R 2 and R 3 together with the nitrogen to which they are attached form a morpholine , Piperidine, piperazine or tetrahydroisoquinoline-3-carboxylic acid residue, and wherein the carbon atoms in the ring are unsubstituted or mono- or disubstituted by
• R 2 and R 3 together with the nitrogen to which they are attached form a 4- to 7-membered ring, in which one of the carbon atoms is optionally replaced by -O-, -S- or -NH-" understood, which are derived, for example, from azetidine, pyrroline, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, tetrahydroisoquinoline or tetrahydroisoquinoline-3-carboxylic acid (TIC).
• TIC tetrahydroisoquinoline-3-carboxylic acid
• R 8 and R 7 together with the carbon to which they are attached form a 4- to 7-membered ring is understood to mean residues which are derived, for example, from azetidine, pyrroline, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, Derive tetrahydroisoquinoline or tetrahydroisoquinoline-3-carboxylic acid.
• heteroalkyl ring is understood to mean residues which are derived, for example, from piperidine, azetidine, pyrrolidine, isoxazolidine, morpholine, isothiazolidine, thiomorpholine, pyrazolidine, imidazolidine, piperazine, pyran or thiopyran.
• halogen is understood to mean fluorine, chlorine, bromine or iodine.
• alkyl or “alkenyl” is understood to mean hydrocarbon radicals whose carbon chain is straight-chain or branched. Furthermore, the alkenyl radicals can also contain several double bonds.
• Cyclic alkyl radicals are, for example, 3 - Up to 7-membered monocycles such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
• R 7 means the residue of an ⁇ -amino acid
• Natural amino acid means glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, lysine, histidine, arginine, glutamic acid and aspartic acid.
• unnatural amino acid are meant those compounds of formula II in which, for example, the radical R is modified by further substituents in the natural side chain or R is a phenyl, cycloalkyl, such as cyclohexyl or heteroaryl- (CH 2 ) n as under “R 2 stands for 5 ".
• the characteristic residues of, for example, the following non-naturally occurring amino acids 2-aminoadipic acid, 2-aminobutyric acid, 2-aminoisobutyric acid, 2,3-diaminopropionic acid, 2,4-diaminobutyric acid, 1, 2,3,4-tetrahydroisoquinoline-1-carboxylic acid are preferably 1, 2,3,4-tetrahydroisoquinoline-3-carboxylic acid, 2-aminopimelic acid, phenylglycine, 3- (2-thienyl) -alanine, 3- (3-thienyl) -alanine, 2- (2-thienyl) -glycine, 2- aminoheptanoic acid, pipecolic acid, hydroxylysine, sarcosine, N-methylisoleucine, 6-N-methyllysine, N-methylvaline, norvaline, norleucine, ornithine, allo-isoleucine, allo-threon
• the invention further relates to a process for the preparation of the compound of the formula I and / or a stereoisomeric form of the compound of the formula I and / or a physiologically tolerable salt of the compound of the formula I, which is characterized in that a) an amine of the formula III,
• R 2 and R 3 are as defined in formula I, with a sulfonic acid derivative of the formula IV,
• R 1 is as defined in formula I and Y is a halogen atom, imidazolyl, or
• R 10 represents hydrogen atom, (CC 6 ) alkyl, phenyl or benzyl, in the presence of a base or optionally a dehydrating agent to give a compound of the formula I, or
• R 1 has the meaning given above, in the presence of sodium hypochlorite or chlorine and an amine of the formula in a sulfenamine of the formula VI,
• R 1 , R 2 and R 3 have the meaning given above, and the compound of the formula VI in the presence of an oxidizing agent such as peracids, in particular peracetic acid, m-chloroperbenzoic acid or hydrogen peroxide or potassium permanganate is converted into the compound formula I, or
• the compound of the formula I prepared by process a) or b) is either isolated in free form or, if acidic or basic groups are present, converted into physiologically tolerable salts.
• 5-Mercaptothiadiazoles of the formula V which are usually prepared by introducing chlorine into a suspension of the compound of the formula V in a mixture of acetic acid and water in a ratio of 1, serve as starting products for the preparation of a sulfonic acid derivative of the formula IV, in particular if Y represents a chlorine atom : 2 to 5: 1 are oxidized directly to the corresponding sulfonic acid chlorides of the formula IV at reaction temperatures of 0 ° C. to 30 ° C.
• a compound of the formula I is prepared by process route b) via the sulfenamides of the formula VI, which preferably consist of a 5-mercaptothiadiazole of the formula V and an amine of the formula III in an aqueous medium with sodium hypochlorite at reaction temperatures from -5 ° C. to 35 ° C arise.
• peracids such as peracetic acid, m-chloroperbenzoic acid, potassium permanganate or hydrogen peroxide are preferably used (as described in US 4,985,450).
• physiologically compatible salts from compounds of the formula I capable of salt formation, including their stereoisomeric forms, is carried out in a manner known per se.
• the acids which may be present form, with basic reagents such as hydroxides, carbonates, hydrogen carbonates, alcoholates and ammonia or organic bases, for example trimethyl- or triethylamine, ethanolamine or triethanolamine or also basic amino acids, for example lysine, ornithine or arginine, stable alkali metal, alkaline earth metal or optionally substituted ammonium salts.
• basic reagents such as hydroxides, carbonates, hydrogen carbonates, alcoholates and ammonia or organic bases, for example trimethyl- or triethylamine, ethanolamine or triethanolamine or also basic amino acids, for example lysine, ornithine or arginine, stable alkali metal, alkaline earth metal or optionally substituted ammonium salts.
• stable acid addition salts can also be prepared with strong acids.
• Both inorganic and organic acids such as hydrogen chloride, hydrogen bromide, sulfur, phosphorus, methanesulfone, benzenesulfone, p-toluenesulfone, 4-bromobenzene-sulfonic, cyclohexylamidosulfonic, trifluoromethylsulfonic, acetic, oxalic, tartaric, succinic or trifluoroacetic acid in question.
• the invention also relates to pharmaceuticals, characterized by an effective content of at least one compound of the formula I and / or a physiologically tolerable salt of the compound of the formula I and / or an optionally stereoisomeric form of the compound of the formula I, together with a pharmaceutically suitable and physiologically compatible carrier, additive and / or other active substances and auxiliaries.
• IL-1 ⁇ and its disease-causing effects are described in the patent EP 0 607 775, US 5 556 870 and in the literature cited therein.
• the compounds according to the invention are suitable for the prophylaxis and therapy of diseases which are characterized by IL-1ß, or also those in whose formation IL-1ß is involved, but especially those in the course of which increased concentrations of IL-1 ⁇ 1 ß are involved.
• the diseases to be treated include, for example, leukemia, septic shock, hepatitis, HIV infections or musculoskeletal diseases such as muscle breakdown, degenerative joint diseases such as osteoarthrosis, spondylosis, cartilage loss after joint trauma or prolonged joint immobilization after meniscus or patella injuries or ligament tears.
• This also includes connective tissue diseases such as collagenosis, periodontal diseases, wound healing disorders and, in particular, chronic musculoskeletal disorders such as inflammatory, immunological or metabolic acute and chronic arthritis, arthropathy, rheumatoid arthritis, myalgia and disorders of bone metabolism.
• connective tissue diseases such as collagenosis, periodontal diseases, wound healing disorders and, in particular, chronic musculoskeletal disorders such as inflammatory, immunological or metabolic acute and chronic arthritis, arthropathy, rheumatoid arthritis, myalgia and disorders of bone metabolism.
• the medicaments according to the invention are generally administered orally or parenterally. Rectal or transdermal application is also possible.
• the invention also relates to a process for the preparation of a medicament, which is characterized in that at least one compound of the formula I and, if appropriate, a pharmaceutically suitable and physiologically tolerable carrier brings other suitable active ingredients, additives or auxiliaries into a suitable dosage form.
• Suitable solid or galenical forms of preparation are, for example, granules, powders, dragees, tablets, (micro) capsules, suppositories, syrups, juices,
• Suspensions, emulsions, drops or injectable solutions as well as preparations with a protracted active ingredient release in the production of which conventional auxiliaries, such as carriers, explosives, binders, coatings, swelling agents, lubricants or lubricants, flavors, sweeteners and solubilizers, are used .
• auxiliaries such as carriers, explosives, binders, coatings, swelling agents, lubricants or lubricants, flavors, sweeteners and solubilizers
• Magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, cellulose and its derivatives, animal and vegetable oils such as cod liver oil, sunflower, peanut or sesame oil, polyethylene glycol and solvents such as sterile are common additives Water and mono- or polyhydric alcohols such as glycerine.
• the pharmaceutical preparations are preferably produced and administered in dosage units, each unit containing as active ingredient a certain dose of the compound of the formula I according to the invention.
• this dose can be up to about 1000 mg, but preferably about 50 to 300 mg and at
• Injection solutions in ampoule form up to about 300 mg, but preferably about 10 to 100 mg.
• daily doses for the treatment of an adult patient weighing approximately 70 kg, daily doses of approximately 20 mg to 1000 mg of active ingredient, preferably approximately 100 mg to 500 mg, are indicated, depending on the effectiveness of the compounds according to formula I. Under certain circumstances, however, higher or lower daily doses may also be appropriate.
• the daily dose can be administered either by single administration in the form of a single dosage unit or else several smaller dosage units, or by multiple administration of divided doses at certain intervals.
• R Lymphoprep
• the cell fraction which appeared as a white ring in the phase boundary was withdrawn with the aid of a syringe, diluted 1: 1 (v / v) with PM-16 buffer (from Serva, Heidelberg, FRG), and again, as above, for 10 centrifuged min.
• the supernatant was added with 10 ml of RPMI 1640 buffer (Gibco, Berlin, FRG), which previously had 300 mg / l L-glutamine, 25 mmol / l HEPES, 0.1 g / ml streptomycin and 0.1 g / ml penicillin had been included.
• the cell suspension which consists of approximately 90% lymphocytes and 10% monocytes, was adjusted to approximately 5 million cells / ml.
• the cell viability was checked before and after the inhibition experiments using the known lactate dehydrogenase method. No change in viability was found.
• the synthesis and release of cellular IL-1 ⁇ was induced by adding a solution of 500 mg lipopolysaccharide (Salmonella abortus equi, Sigma GmbH, Deisenhofen, FRG) to 0.01 ml of the cell fraction described above in 0.01 ml dimethyl sulfoxide / water ( 1:10, v / v) was given.
• test substance in 0.01 ml was added to the cell fraction and it was left in a commercially available incubator at 37 ° C. for 20 hours. After the samples had been cooled to 0 ° C., centrifugation was carried out for 1 minute in a table centrifuge, and 0.025 ml aliquots of the supernatant were specifically made using a commercially available “sandwich” enzyme immunoassay kit (from Biosource, Ratingen, FRG) according to the manufacturer's instructions The control values were determined without addition of test preparation and set to 100%. In particular, corresponding comparative measurements excluded any influence of dimethyl sulfoxide on the IL-1 ß level.
• the dose-dependent IL-1 ⁇ -inhibiting activity of a compound of the formula I was demonstrated by determining its potency (complete inhibition of the IL-1 ⁇ release corresponds to 100% inhibition) at seven different concentrations.
• the concentration range was chosen so that it comprised the ranges from 0% inhibition (ie without test substance addition) to at least 80% inhibition. From the graphically or arithmetically determined dose-response relationship the test substance concentration was extrapolated, which led to 50% inhibition of the IL-1 ⁇ release.
• This IC 50 value was shown in Table 2 as micromol / liter for the corresponding compounds of the formula I according to the invention.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Physical Education & Sports Medicine (AREA)
• Rheumatology (AREA)
• Hematology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Virology (AREA)
• Oncology (AREA)
• Immunology (AREA)
• Diabetes (AREA)
• Pain & Pain Management (AREA)
• Tropical Medicine & Parasitology (AREA)
• AIDS & HIV (AREA)
• Communicable Diseases (AREA)
• Molecular Biology (AREA)
• Gastroenterology & Hepatology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=7884736

Family Applications (1)

Country Status (11)

Families Citing this family (7)

Citations (1)

Family Cites Families (7)

• 1998
  • 1998-10-16 DE DE19847823A patent/DE19847823A1/de not_active Withdrawn
• 1999
  • 1999-10-02 DK DK99947450T patent/DK1121349T3/da active
  • 1999-10-02 AT AT99947450T patent/ATE263158T1/de active
  • 1999-10-02 WO PCT/EP1999/007301 patent/WO2000023430A1/de not_active Ceased
  • 1999-10-02 AU AU60887/99A patent/AU6088799A/en not_active Abandoned
  • 1999-10-02 JP JP2000577158A patent/JP4733270B2/ja not_active Expired - Fee Related
  • 1999-10-02 PT PT99947450T patent/PT1121349E/pt unknown
  • 1999-10-02 EP EP99947450A patent/EP1121349B1/de not_active Expired - Lifetime
  • 1999-10-02 ES ES99947450T patent/ES2214885T3/es not_active Expired - Lifetime
  • 1999-10-02 DE DE59909049T patent/DE59909049D1/de not_active Expired - Lifetime
  • 1999-10-14 US US09/418,026 patent/US6218412B1/en not_active Expired - Lifetime
  • 1999-10-14 AR ARP990105202A patent/AR023909A1/es active IP Right Grant
• 2001
  • 2001-02-09 US US09/779,823 patent/US6503934B2/en not_active Expired - Lifetime

Patent Citations (1)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events